Better Health, Brighter FutureNews Release

Takeda Disposes of Real Estate through Absorption-type Company Split and Share Transfer-OSAKA,

Transfer of real estate, including the Osaka Headquarters (Takeda Mido-suji Building)JAPAN,January

28,

2019

–TakedaPharmaceutical-Company

Limited(TSE:4502/NYSE:TAK) (Headquarters: Chuo-ku, Osaka, “Takeda”) today announced that it has decided
to newly establish a wholly owned subsidiary (“Subject Company”) of Takeda Pharmaceutical Real EstateCo., Ltd. (Headquarters: Chuo-ku, Tokyo, “TPRE”), a wholly owned subsidiary of Takeda; to have the
Subject Company succeed a portion of the real estate businesses of both Takeda and TPRE throughabsorption-type company splits as of March 11, 2019 (“Company Split”); and to transfer all the shares of the
Subject Company held by Takeda and TPRE as of March 22, 2019 (“Share Transfer” combined with theCompany Split as the “Transaction”).
After the Transaction, the transferee will hold 21 assets, including the Takeda Osaka Headquarters building(Takeda Mido-suji building). The transfer price is undisclosed upon request from the transferee of the shares,
which is an unlisted company. Takeda will record a gain of approximately 38 billion yen (before taxes) as aresult of the transfer in the second half of fiscal year 2018. Business activities of Takeda at these locations,such as Osaka Headquarters (Takeda Mido-suji building), will continue after the completion of theTransaction.
Since the Company Split is an absorption-type company split carried out between Takeda and its wholly
owned subsidiaries, certain details will be abridged, in line with the Tokyo Stock Exchange disclosure
guidelines.

1. Purpose and reason for the TransactionTakeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. TPRE is awholly-owned subsidiary of Takeda that is engaged in the selling and buying, management, leasing, etc. of
the real estate in Japan held by Takeda Pharmaceutical Group companies.
Takeda has for some time been taking steps to securitize its non-core fixed assets and businesses, and expand
its investment for future success to drive innovation. This Transaction provides another way for Takeda toimprove its investment efficiency through the global review of Takeda's business resources and construct a
more robust financial profile. Takeda will continue to look into possible sales of non-core assets worth up to10 billion US dollars to further decrease Takeda’s leverage (net debt to adjusted EBITDA ratio) and optimize
its business resources.

12. Details of the Transaction(1) Schedule of the Transaction[1] Between Takeda and the Subject Company
Date of decision on absorption-type company split agreement

January 28, 2019by the Director delegated by the Board of Directors
Date of conclusion of agreement on share transfer

January 28, 2019

Date of conclusion of absorption-type company split agreement

February 1, 2019

Effective date of absorption-type company split

March 11, 2019 (Scheduled)

Date of transfer of shares

March 22, 2019 (Scheduled)(Note) The Company Split is to be conducted by Takeda in accordance with Article 784, paragraph 2 of the Companies Act.
Accordingly, no approval by a general meeting of shareholders as defined in Article 783, paragraph 1 of the Companies
Act is required.

[2] Between TPRE and the Subject Company
Date of approval of absorption-type company split agreement

January 28, 2019by the Board of Directors of TPRE
Date of conclusion of agreement on share transfer

January 28, 2019

Date of conclusion of absorption-type company split agreement

February 1, 2019

Date of approval of absorption-type company split by a general

February 19, 2019 (Scheduled)meeting of shareholders of TPRE
Effective date of absorption-type company split

March 11, 2019 (Scheduled)

Date of approval of transfer of shares by a general meeting ofMarch 13, 2019 (Scheduled)shareholders of TPRE
Date of transfer of shares

March 22, 2019 (Scheduled)(2) Method of Company Split
In the Company Split, Takeda and TPRE will be the splitting companies, and the Subject Company will be
the succeeding company.
(3) Details of stock allocation
As consideration for the rights and obligations to be succeeded as a result of the Company Split, the Subject
Company will issue 59,423 shares of common stock and allocate 4,783 shares to Takeda and 54,640 shares toTPRE, respectively.
(4) Treatment of stock options and corporate bonds with stock options with regards to the Company Split
Although Takeda has issued stock options, there will be no change in the treatment of these stock options dueto the Company Split.
No corresponding options exist for TPRE.
(5) Increase or decrease of capital stock due to the Company Split
There will be no increase or decrease of Takeda's capital stock and TPRE due to the Company Split.

2(6) Rights and obligations to be succeeded by the Subject Company
The Subject Company will, based on the absorption-type company split agreements with Takeda and with
TPRE respectively, succeed assets relating to the business to be split off in accordance with the terms andconditions of absorption-type company split agreement, as well as the rights and obligations incidental
thereto.
Succession of debts and other obligations from Takeda and TPRE to the Subject Company based on thecompany split agreement is to be made by the method of assumption of obligations without specificliabilities.
(7) Capability of satisfying liabilities
In the Company Split, Takeda has judged that the Subject Company will not have any problem in performing
its obligations relating to the liabilities it will bear following the effective date of the absorption-typecompany splits; however, Takeda and TPRE will not be liable for the Subject Company’s liabilities as aguarantor.
3. Outline of the companies(1) Company name(2) Location

Splitting company A

Splitting company B(As of March 31, 2018)(As of March 31, 2018)

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Real EstateCo., Ltd.

1-1, Doshomachi 4-chome, Chuo-ku, Osaka,

1-1, Nihonbashi Honcho 2-chome,Japan

Chuo-ku, Tokyo, Japan(3) Representative

President & Representative
President & CEO: Christophe Weber

Director:
Yasuhisa Yamamoto(4) Scope of businessResearch and development, manufacturing,Selling and buying, management,

sales and marketing of pharmaceuticalleasing, etc. of real estate

products, etc.
(5) Capital

77,914 million yen

100 million yen(6) Date established

January 29, 1925

June 26, 2006

(7) Number of shares 794,688,295 shares

20,000 sharesissued(8) Fiscal year end

March 31

March 31(9) Major shareholders

The Master Trust Bank of Japan,and ratio of sharesLtd. (Trust account)

held

Nippon Life Insurance Company

5.48%

JP MORGAN CHASE BANK

4.41%

5.92%

Takeda 100%

380055
Japan Trustee Services Bank,

4.33%

Ltd. (Trust account)
Takeda Science Foundation

2.25%
3

(10) Financial results of the previous fiscal year (consolidated, IFRS)
Takeda Pharmaceutical Company Limited
Total equity

1,997,424 million yen

Total assets

4,106,463 million yen

Equity attributable to owners of the company

2,556.51 yen

per share
Revenue

1,770,531 million yen

Operating profit

241,789 million yen

Profit before income taxes

217,205 million yen

Profit attributable to owners of the company

186,886 million yen

Basic earnings per share

239.35 yen

Dividend per share180.00 yen
Succeeding company (Subject Company) (As of January 17,2019)(1) Company nameTYF Business Preparation Company KK(2) Location

1-1, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo, Japan(3) Representative

President & Representative Director: Yukio Ajuuta(4) Scope of businessSelling and buying, management, leasing, etc. of real estate(5) Capital

10 million yen(6) Date established

January 17, 2019(7) Number of shares issued

10 shares(8) Fiscal year end

March 31(9) Major shareholders and ratio of shares

Takeda Pharmaceutical Real Estate Co., Ltd. 100%

held4. Outline of the businesses to be split off from Takeda and TPRE to the Subject Company(1) Details of the business to be split off
The portion of the business to be split off is a part of real estate businesses of Takeda and TPRE including
but not limited to selling and buying, management and leasing of real estate.
(2) Financial results of the business to be split off
The businesses to be split off have not recorded external revenue.
(3) Book value of assets and liabilities to be split off (as of March 31, 2018)
AssetsItem

Liabilities
Book value

ItemBook value

Current assets

1,846 million yen Current liabilities

288 million yen

Fixed assets

11,049 million yen Fixed liabilities

1,917 million yenTotal

12,895 million yen Total

2,205 million yen(Note) Figures were calculated based on the balance sheet as of March 31, 2018; therefore, the actual amounts to be succeeded
will be increased or decreased, reflecting changes until the effective date.

45. Status of the companies after the Company Split(1)

There will be no change in Takeda’s and TPRE’s company name, location, name and title of its
representatives, scope of business, capital, or fiscal period after the Company Split.

(2)

The capital of the Subject Company will not change as a result of the Company Split.

6. Share Transfer(1) Profile of the subsidiary (Subject Company) to undergo changes
Please see 3. above for descriptions of the Subject Company.

(2) Transferee of the Share Transfer
The transferee is undisclosed upon request from the transferee of the shares, which is an unlisted company.
There are no capital, human, or trading relationships, or applicable related parties between the transferee andTakeda as well as TPRE.

(3) Change in ownership of shares through the Share Transfer(1) Number of shares held prior to the transfer(2) Number of shares to be transferred(3) Number of shares held after the transfer

59,433shares(Takeda 4,783 shares, TPRE 54,650 shares)
59,433 shares(Takeda 4,783 shares, TPRE 54,650 shares)
Takeda 0 shares (Ownership ratio: 0%),TPRE 0 shares (Ownership ratio: 0%)(Note) The transfer price is undisclosed upon request from the transferee of the shares, which is an unlisted company.

7. Future outlook
Takeda’s consolidated financial forecast for fiscal year 2018, which was announced on October 31, 2018,
includes 80 billion yen as a gain on sale of real estate, and this Transaction is a portion of this.
(Reference) Consolidated earnings forecast for this fiscal year (announced on October 31, 2018) andconsolidated results for the previous fiscal year (in million yen)

RevenueEarnings forecastfor this fiscal year
(year ending
March 2019)
Results for theprevious fiscalyear (year ended
March 2018)

Operating profit

Profit before
income taxes

Net profit
attributable toowners of thecompany

1,750,000

268,900

245,200

189,500

1,770,531

241,789

217,205

186,886(Note) The revised forecast in the table above includes the costs incurred in the first half of fiscal 2018 related to the proposed
acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion JPY, Net profit for the year impact: 16.5 billion
JPY); however, it does not include Shire-related costs anticipated to be incurred in the second half of the fiscal year.

###5[Appendix: Transaction Steps][STEP1: Establishment of theSubject Company][Current status]

TakedaTakeda100%

100%TPRE

TPRE

100%

Subject Company[STEP4: Share Transfer][STEP3: Company Split]

Transfer ofshares

TakedaTakedaPayment for transfer

TPREShares

TPRE

Realestate
Realestate

SubjectCompanyTransferee

Transfer ofshares

SharesSubjectCompany

6

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based,
R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better
Health and a Brighter Future to patients by translating science into highly-innovative medicines.
Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI),Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived
Therapies and Vaccines. We are focusing on developing highly innovative medicines that
contribute to making a difference in people's lives by advancing the frontier of new treatment
options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust,modality-diverse pipeline. Our employees are committed to improving quality of life for patientsand to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com

Investor Relations Contact:
Takashi Okubo
takeda.ir.contact@takeda.com+81 3 3278 2306
Media Inquiries:
Tsuyoshi Tada (Outside of Japan)
Tsuyoshi.Tada@takeda.com+1 617 551 2933
Kazumi Kobayashi (Japan)
Kazumi.kobayashi@takeda.com+81 3 3278 2095

7